1 Mitral Annular Disjunction in Heritable Thoracic Aortic Disease: Insights From the Montalcino

- 2 Aortic Consortium
- 3 Short Title: MAD in Thoracic Aortic Disease
- 4 Total Word Count: 2380
- 5 Kishan L. Asokan; Kishan.L.Asokan@uth.tmc.edu; University of Texas Health Science Center at
- 6 Houston, Houston, TX, USA
- 7 Jennifer R. Landes; Jennifer.R.Landes@uth.tmc.edu; University of Texas Health Science Center at
- 8 Houston, Houston, TX, USA
- 9 Wannes Renders, MD; Wannes.Renders@ugent.be; Ghent University, Ghent, Belgium
- 10 Laura Muiño Mosquera, MD, PhD; laura.muinomosquera@uzgent.be; Ghent University Hospital, Ghent,
- 11 Belgium
- 12 Julie De Backer, MD, PhD; julie.debacker@ugent.be; Ghent University Hospital, Ghent, Belgium
- 13 David W Jantzen, MD; tjantzen@childrensnebraska.org; University of Nebraska Medical Center, Omaha,
- 14 NE, USA
- 15 Anji T. Yetman, MD; ayetman@childrensnebraska.org; University of Nebraska Medical Center, Omaha,
- 16 NE, USA
- 17 Gisela Teixido-Tura, MD, PhD; gisela.teixido@vallhebron.cat; University Hospital Vall d'Hebron,
- 18 Barcelona, Spain
- 19 Arturo Evangelista, MD; arturevangelistamasip@gmail.com; University Hospital Vall d'Hebron,
- 20 Barcelona, Spain
- 21 Richmond Jeremy, MB.BS, PhD; richmond.jeremy@sydney.edu.au; University of Sydney, Sydney,
- 22 Australia
- 23 Edward G. Jones, MD; edward.jones@bcm.edu; Texas Children's Hospital, Houston, TX, USA
- 24 Shaine Morris; MD, MPH; shainem@bcm.edu; Texas Children's Hospital, Houston, TX, USA

- 3
- 25 Tam Doan; MD; Tam.Doan@bcm.edu; Texas Children's Hospital, Houston, TX, USA
- 26 Maral Ouzonian; MD, PhD; maral.ouzounian@uhn.ca; University of Toronto, Toronto, Canada
- 27 Alan Braverman; MD; abraverm@wustl.edu; Washington University School of Medicine, St Louis, MO,
- 28 USA
- 29 Guillaume Jondeau; MD, PhD; guillaume.jondeau@aphp.fr; Hospital Bichat-Claude Bernard, Paris,
- 30 France
- 31 Olivier Milleron, MD; olivier.milleron@aphp.fr; Hospital Bichat-Claude Bernard, Paris, France
- 32 Siddharth K. Prakash, MD, PhD; Siddharth.K.Prakash@uth.tmc.edu; University of Texas Health Science
- 33 Center at Houston, Houston, TX, USA
- 34 Dianna M. Milewicz, MD, PhD; Dianna.M.Milewicz@uth.tmc.edu; University of Texas Health Science
- 35 Center at Houston, Houston, TX, USA
- 36
- 37 Corresponding Author:
- 38 Siddharth K. Prakash, MD, PhD
- 39 Department of Internal Medicine
- 40 John P and Kathrine G McGovern Medical School
- 41 University of Texas Health Science Center at Houston
- 42 6431 Fannin Street
- 43 MSB 6.116
- 44 Houston, Texas 77030 USA
- 45 Siddharth.K.Prakash@uth.tmc.edu

4

46 Abstract

| 47 | Background: Mitral annular disjunction (MAD), posterior displacement of the mitral valve leaflet hinge |
|----|---|
| 48 | point, predisposes to arrhythmias or sudden cardiac death. We evaluated the burden of MAD, mitral valve |
| 49 | prolapse (MVP), and mitral regurgitation (MR) by heritable thoracic aortic disease (HTAD) gene in a |
| 50 | cross-sectional analysis of 2014-2023 data in the Montalcino Aortic Consortium (MAC) registry. |
| 51 | Methods: MAD was determined by direct measurement of echocardiographic images. MR and MVP were |
| 52 | defined according to current clinical guidelines. Associations were evaluated using chi-squared or Fisher |
| 53 | exact tests. |
| 54 | Results: MR and MVP were enriched in MAC participants (672) with pathogenic variants (PV) in TGF- β |
| 55 | pathway genes. The combination of MR and MVP was associated with mitral surgery and arrhythmias. In |
| 56 | the subgroup with available images, MAD was enriched in SMAD3 PV compared to other TGF- β PV (PR |
| 57 | 1.8 [1.1-2.8], $P < 0.02$). Severe disjunction (>10 mm) was only observed in the TGF- β subgroup and was |
| 58 | further enriched in participants with SMAD3 PV (PR 3.1 [1.1-8.6]). MVP (PR 5.2 [3.0-9.0]) and MR (PR |
| 59 | 2.7 [1.8-3.9) were increased in participants with MAD, but MAD was not independently associated with |
| 60 | adverse cardiac or aortic events. |
| 61 | Conclusions: Mitral phenotypes are more prevalent in individuals with PV in TGF- β pathway genes, |
| 62 | particularly SMAD3, and are associated with adverse aortic and cardiac events. Because congenital mitral |
| 63 | disease may be the primary presenting feature of SMAD3 PV, genetic testing for HTAD should |
| 64 | be considered for such individuals, especially if they also have a family history of HTAD. |

5

- 65 Indexing terms: Thoracic aortic aneurysms and dissections, congenital heart disease, mitral valve, Loeys-
- 66 Dietz syndrome, cardiovascular genetics
- 67
- 68 Nonstandard Abbreviations and Acronyms
- 69 LDS Loeys-Dietz syndrome
- 70 MAD Mitral Annular Disjunction
- 71 MFS Marfan syndrome
- 72 SCD Sudden Cardiac Death
- 73 HTAD Heritable Thoracic Aortic Disease
- 74 TGF-β Transforming Growth Factor-Beta
- 75

76 Clinical/Research Perspective

77 What Is New?

1) Mitral regurgitation, mitral valve prolapse, and mitral annular disjunction (MAD) are common in

⁷⁹ heritable thoracic aortic disease (HTAD) caused by pathogenic variants (PV) in TGF- β pathway genes

80 (SMAD3, TGFBR1, TGFBR2, TGFB2, or TGFB3) and are associated with adverse cardiac events.

81 2) Pathological mitral phenotypes are particularly prominent in people with SMAD3 PV and may be the

82 presenting feature of HTAD in some cases.

83 What Are the Clinical Implications?

84 3) Pathological mitral valve phenotypes may identify a high-risk subgroup of HTAD cases with more

- 85 frequent adverse cardiovascular events. Because congenital mitral disease may be the primary presenting
- 86 feature of SMAD3 PV, genetic testing for HTAD should be considered for such individuals, especially if
- 87 they also have a family history of HTAD.
- 88

6

89 Introduction

| 90 | Mitral annular disjunction (MAD) is atrial displacement of the mitral valve leaflet hinge point |
|-----|--|
| 91 | from the ventricular myocardium. MAD was first described in autopsy studies of individuals with mitral |
| 92 | valve prolapse (MVP) who experienced sudden cardiac death (SCD) [1, 2]. MVP or MAD may pose an |
| 93 | increased risk for ventricular arrhythmias and SCD, and MAD is an independent risk factor for arrhythmic |
| 94 | events [2-8]. Cardiac magnetic resonance studies identified myocardial fibrosis in the inferolateral left |
| 95 | ventricle of MAD cases and implicated significant fibrosis as a nidus for ventricular arrhythmias [6]. In |
| 96 | Marfan syndrome (MFS), MAD also predisposes to ventricular tachycardia and SCD, and displacement of |
| 97 | the mitral hinge point > 10 mm is correlated with the likelihood of ventricular arrhythmias [4, 9]. The |
| 98 | genetic cause of most sporadic MAD cases and potential associations between pathogenic variants (PV) in |
| 99 | other HTAD genes and MAD are unknown. |
| 100 | The Montalcino Aortic Consortium (MAC, NCT04005976) is an international collaboration of |
| 101 | expert HTAD clinical centers that was established in 2013 to investigate the disease course of individuals |
| 102 | with validated PV in a clinically actionable HTAD gene [10, 11]. Genetic syndromes (e.g. Marfan |
| 103 | syndrome or Loeys-Dietz syndrome) cause approximately 5% of HTAD cases, with the vast majority |
| 104 | classified as non-syndromic [12]. Known causative HTAD genes encode extracellular matrix proteins |
| 105 | (FBN1, COL3A1, LOX), components of the TGF-β signaling pathway (SMAD2, SMAD3, SMAD4, TGFB2, |
| 106 | TGFB3, TGFBR1, TGFBR2), and smooth muscle cell contractile components (ACTA2, MYLK, PRKG1, |
| 107 | MYH11). [12,13][16]. More than 20% of individuals with non-syndromic HTAD have a family history of |
| 108 | HTAD, signaling the urgent need for early diagnosis and surveillance of affected individuals [13, 14]. The |
| 109 | MAC data on the natural history of HTAD due to specific PV have informed new clinical |
| 110 | recommendations for management of HTAD based on the underlying mutated gene in the 2022 |
| 111 | ACC/AHA Guidelines for the Diagnosis and Management of Aortic Disease [13, 17]. The specific type of |
| 112 | PV may influence the timing of elective surgery to prevent an aortic dissection because some PV are |
| 113 | associated with dissections at smaller absolute aortic diameters. |

| ٢ | | | ľ | |
|---|---|---|---|--|
| | | | | |
| | 4 | 1 | | |
| | | | | |

Aneurysms and dissections of smaller arteries and congenital cardiac malformations such as bicuspid aortic valve and septal defects are more common in some HTAD PV carriers [18][19][20]. We hypothesize that mitral valve prolapse (MVP), mitral regurgitation (MR), or MAD may be enriched in groups with HTAD PV due to phenotypic overlap between MAD, MFS, and HTAD. This study focused on the analysis of mitral phenotypes including MAD in the MAC cohort and potential associations with the mutated HTAD gene.

- 120
- 121 Methods

We conducted a multicenter cross-sectional study of MAC registry participants. The study protocol 122 was reviewed and approved by the Committee for the Protection of Human Subjects at the University of 123 124 Texas Health Science Center at Houston (IRB HSC-MS-16-0191). The investigators accessed person-125 level data from a single registry to create the study population. Additional data or clarifications were 126 requested from the enrolling site investigators as needed. The data collection period was from 12/2014 to 127 8/2023. We considered pathogenic and likely pathogenic variants as a single group for analysis (referred 128 to as PV). Participants without validated HTAD gene PV were excluded from the analysis. We also 129 excluded individuals with FBN1 PV because MAC exclusively enrolled pediatric FBN1 cases at the time 130 of this analysis.

The primary independent variable was mitral disease, defined as any degree of mitral valve prolapse (MVP), or mild, moderate, or severe mitral regurgitation (MR). The primary dependent variables were clinical outcomes: the diagnosis of any arrhythmia, congestive heart failure (CHF), or aortic dissection, or aortic or mitral valve surgery. The principal covariates were sex and the HTAD PV. For the subgroup of MAC participants with available images, the primary independent variable was MAD. MAD distance was measured by direct review of echocardiogram images. We determined that MAD was present if we measured at least three millimeters between the posterior mitral valve leaflet

hinge point and the inferolateral myocardium using the inner edge to inner edge method [5]. MAD was

8

measured during mid-systole at the peak of the T wave in the parasternal long axis view. Two experienced
reviewers reported the mean of three measurements for each cine series.

141 Parasternal long axis images were rated using American Society of Echocardiography criteria for 142 orientation and image quality. Orientation was acceptable if the horizontal septum deviated less than 30 143 degrees from the horizontal plane, the proximal aorta aortic and mitral valves were visible, and the 144 ventricular septum was visible to the apex. Image quality was assessed by brightness level, resolution, and focus on the region of interest. Reviewers rated each category as optimal, adequate, or inadequate. If any 145 146 category was inadequate, the image was excluded from analysis. 147 Pearson's chi-squared tests or Fisher exact tests were used for comparisons of categorical data. 148 Ouantitative data were described using median values with interquartile ranges. The strength of 149 associations was assessed by calculating the E-values of prevalence ratios (PR) [21]. A multivariate 150 regression model was constructed to evaluate associations between age, sex, mutation type, MAD, MVP, 151 and MR and the composite outcome of aortic surgery, mitral surgery, aortic dissection, arrhythmia, or 152 CHF using DATAtab (DATAtab e.U. Graz, Austria).

153

154 **Results**

From an initial sample of 1080 MAC participants, 130 subjects were excluded due to missing 155 156 genotypes. 203 participants were excluded due to missing MR or MVP phenotypes, and 75 were excluded 157 for missing variant pathogenicity classifications. A total of 672 MAC participants (51% male, median age 36 years [IQR 19,51]) were included in this study: 312 (46%) had PV in TGF-β pathway genes. Images 158 159 from 240 participants were used to assess MAD (50% male, median age 33 years [IQR 20,33]). Nine 160 subjects were excluded from the MAD sub-study due to image quality. Three quarters of MAC 161 participants had a PV in an HTAD gene (Table 1). Participants with variants of uncertain significance 162 (n=155) were excluded from this analysis.

164 <u>Mitral Valve Disease in the MAC Cohort</u>

| Δ |
|---|
| 9 |

| 165 | The prevalence of MR and MVP in the United States Population is estimated at 2-3% [23, 24]. In |
|-----|---|
| 166 | the MAC cohort, the overall prevalence of MR was 22%, the prevalence of moderate or severe MR was |
| 167 | 3%, and the prevalence of MVP was 14% (Table 1). Therefore, MR and MVP are 5-10 times more |
| 168 | prevalent in MAC than in the general population. There were no significant differences in the prevalence |
| 169 | of MR or MVP in males vs. females, or in individuals with PV compared to individuals with VUS (Figure |
| 170 | S1 and Figure S2). |
| 171 | Most individuals with MVP had PV in TGF- β pathway genes (Table 2). Individuals with <i>SMAD3</i> , |
| 172 | TGFBR1, TGFBR2, TGFB2, or TGFB3 PV comprised 60% of the MAC cohort with PV but 90% of MVP |
| 173 | and 71% of MR cases (Figure S3). The number of MAC participants with ACTA2 and TGFBR2 PV were |
| 174 | similar, but MVP was seven times more common in the subgroup with TGFBR2 PV compared to the |
| 175 | subgroup with ACTA2 PV (17/83 (20%) vs. 3/89 (3%), PR 6.1 [1.8-20], P<0.001). |
| 176 | The proportion of individuals with MVP or mild, moderate, or severe MR was significantly |
| 177 | enriched in TGFBR1 and SMAD3 PV carriers (Figure S3 and Figure S4). The prevalence of MR was more |
| 178 | evenly distributed between groups with PV in other HTAD genes such as ACTA2 (18%, Table 2). |
| 179 | Cardiac outcomes of MAC participants with mitral disease were significantly worse than the |
| 180 | outcomes of participants who did not have MVP or MR. Mitral valve surgery (4/32 (13%) vs. |
| 181 | 2/367 (0.5%), PR 23 [4.4-120], P<0.001) and arrhythmias (6/32 (19%) vs. 13/367 (4%), PR 5.3 |
| 182 | [2.2-13], P<0.01) were significantly increased in the group of MAC participants with MVP and MR when |
| 183 | compared to the group without MVP or MR (Table 3). |
| 184 | The prevalence of moderate or severe MR was not significantly different in MAC participants with |
| 185 | PV in TGF- β pathway genes compared to PV in other HTAD genes (<i>P</i> <0.06). Individuals with moderate |
| 186 | or severe MR more frequently had a ortic surgery ($P < 0.01$), mitral surgery ($P < 0.001$), CHF ($P < 0.001$), |
| 187 | and arrhythmias (P <0.01, Table S2). In the subgroup of participants with available images, the composite |
| 188 | of MAD, MVP, and moderate or severe MR was more prevalent in participants with SMAD3 PV |

10

189 compared to those with PV in other HTAD genes (34/67 (51%) vs. 41/172 (24%), PR 2.1 [1.5-3.0],

190 *P*<0.001).

The proportions of probands and relatives who had MVP or MAD were not significantly different, but more probands exhibited the composite clinical endpoint. These findings suggest that the presentation of mitral valve disease was similar in probands and relatives (Table S3).

194

195 Mitral annular disjunction in the MAC cohort

196 Most mitral images were from individuals with PV in TGF- β pathway genes (68%), consistent

197 with the proportion of the TGF- β subgroup in the entire MAC cohort. MAD was observed in 24%

198 (57/240) of the subgroup with available images (Table 4). MAD was more prevalent in MAC participants

199 with PV in TGF- β pathway genes compared to participants with other PV (52/162 (32%) vs. 5/78 (6%),

200 PR 5.0 [2.1-12], P<0.001, Figure 1). MAD was highly enriched in MAC participants with SMAD3 PV

201 compared to PV in other TGF- β pathway genes (29/67 (43%) vs. 23/95 (24%), PR 1.8 [1.1-2.8], P<0.02).

202 MAD, MVP, and/or MR was more prevalent in participants with SMAD3 PV compared to participants

203 with PV in other TGF- β genes (42/67 (63%) vs. 56/95 (41%), PR 1.5 [1.1-2.1], P<0.02). MAD was also

204 enriched in MAC participants with PV in TGFBR1, TGFBR2, and TGFB2 (Figure S5). The overall

205 prevalence of MAD was not significantly different in males (23%, 27/120) compared to females (25%,

 $206 \quad 30/118, P < 0.7)$ or in probands compared to relatives (Table S3).

The prevalence of MVP (26/57 (46%) vs. 16/183 (9%), PR 5.2 [3.0-9.0], P<0.001) and any degree of MR (30/57 (53%) vs 36/182 (20%), PR 2.7 [1.8-3.9], P<0.001), but not moderate or severe MR (8/183 (4%) vs. 4/57 (7%), P<0.3), was increased in MAC participants who had MAD. However, in a logistic regression model with age, sex, MR, MVP, and PV type, MAD was not independently associated with arrhythmia, aortic surgery, aortic dissection, or CHF in the entire MAC cohort or in participants with *SMAD3* PV (Figure S6). Left ventricular ejection fraction, left atrial volume, and the maximum diameter

of the thoracic aorta also did not vary significantly based on the presence of MAD (Table 5).

11

| 214 | The distance between the annulus and myocardial border was measured in 56 MAC participants, |
|-----|--|
| 215 | who were categorized as having mild (3-10 mm, 39) or severe (≥10 mm, 16) disjunction. Severe |
| 216 | disjunction was only observed in MAC participants with TGF- β gene PV and was particularly enriched in |
| 217 | the subgroup with SMAD3 PV (11/67 (16%) vs. 5/95 (5%), PR 3.1 [1.1-8.6], P<0.03). Pathological mitral |
| 218 | phenotypes (>mild MR, severe disjunction, or MAD with MVP) without significant aortic dilation (Z<3) |
| 219 | were present only in MAC participants with PV in TGF- β pathway genes, were enriched in the subgroup |
| 220 | with SMAD3 PV (12/67 (18%) vs. 3/95 (3%), PR 5.7 [1.7-19], P<0.01, Table S4), and were significantly |
| 221 | more prevalent in relatives compared to probands (Table S3). There was no significant difference in the |
| 222 | prevalence of severe annular disjunction between males and females (7/120 (6%) vs. 9/118 (8%)). |

223

224 **Discussion**

In MAC participants with HTAD, we found that the prevalence of MVP was five times higher than 225 226 in the general population and was frequently accompanied by MAD [23, 24]. Our data is consistent with other studies showing that PV in TGF-B pathway genes, primarily TGFBR1 (22%, 11/50), TGFBR2 (20%, 227 228 17/83), TGFB3 (25%, 5/20), and SMAD3 (20%, 16/80, are most strongly associated with these mitral phenotypes [4,25,26,31]. The overall rates of MVP and MAD were 7-8 times higher in MAC participants 229 230 with PV in TGF- β pathway genes than in the rest of the MAC cohort. TGF- β dysregulation can increase 231 matrix metalloproteinase activity and activate endothelial to mesenchymal transition in valve interstitial 232 cells, predisposing to myxomatous mitral valve degeneration [27]. We also identified MAD in MAC participants who did not have PV in TGF- β pathway genes, primarily the subgroup with ACTA2 PV [13]. 233 These data show how the pathophysiology caused by PV in HTAD genes may extend beyond the aorta 234 and highlight potential implications for PV carriers who are at increased risk for cardiac complications 235 236 related to MVP, such as arrhythmias or CHF.

We observed that mitral phenotypes in MAC are significantly associated with aortic surgery,
 mitral surgery, and arrhythmias. It is unclear if mitral and aortic disease are causally linked, or if

12

| 239 | pathological mitral disease with MAD may reflect more severe connective tissue degeneration that |
|-----|--|
| 240 | predisposes to HTAD or myocardial fibrosis driving arrhythmias [28, 29, 31, 32]. The subgroup of MAC |
| 241 | participants with MVP and MR appear to be at particularly high risk for adverse cardiac events. Our data |
| 242 | indicate that this group may benefit from more intensive surveillance or targeted interventions [29, 30]. |
| 243 | In contrast to MAD in MFS, we found that MAD was not independently associated with aortic or |
| 244 | cardiac events in MAC participants. This is likely because most MAC participants with MAD also |
| 245 | presented with MVP. In MFS, the arrhythmic risk that was attributed to MAD occurred predominately in |
| 246 | the context of other mitral phenotypes, with arrhythmias detectable in 40% of individuals who had MVP |
| 247 | and MAD compared to 20% of individuals with MVP and no MAD [8, 33]. In this study, the rate of |
| 248 | arrhythmias in MAC participants who had both MAD and MVP (4/26, 15%) was similar to individuals |
| 249 | who had MAD but no MVP (4/31, 13%). However, these observations do confirm that the risk for |
| 250 | arrhythmias is markedly increased in the subgroup of individuals with HTAD who have pathological |
| 251 | mitral phenotypes and suggest that ambulatory electrocardiographic screening may be beneficial. |
| 252 | Biases due to possible misclassification of individuals with mild mitral phenotypes and missing |
| 253 | phenotypic data may have caused the effect sizes of associations between mitral and clinical phenotypes to |
| 254 | be underestimated. Conversely, we acknowledge that the strength of some associations may be inflated by |
| 255 | unmeasured confounders because a relatively limited set of phenotypes were available for study |
| 256 | participants. In some cases, combined confounding from these factors could reach the magnitude of the E- |
| 257 | value and could nullify a significant association. MAC study sites are referral centers that tend to recruit |
| 258 | participants with more severe HTAD phenotypes than in community settings. Therefore, larger |
| 259 | prospective studies are needed to corroborate these findings and to determine the prognostic significance |
| 260 | of MAD in different genetic and clinical contexts. |
| 261 | |

262 Acknowledgements

We thank the study participants and referring clinicians without whom this study would not have 263

| | 13 |
|-----|---|
| 264 | been possible. Special thanks to Kristin Ankoma-Sey and Walter Velasco-Torrez for assistance with MAC |
| 265 | registry data. The Montalcino Aortic Consortium investigators are: Dianna M. Milewicz, MD, PhD; Reed |
| 266 | Pyeritz, MD, PhD; Julie De Backer, MD, PhD; Catherine Boileau, PhD; Guillaume Jondeau, MD, PhD; |
| 267 | Alan Braverman, MD; Shaine A. Morris, MD; Arturo Evangelista, MD; Maral Ouzounian, MD, PhD; |
| 268 | Anji Yetman, MD; Richmond, Jeremy, MB, BS, PhD; Sherene Shalhub, MD, MPH; Eloisa Arbustini, |
| 269 | MD; Lesley Ades, MD; Nanette Alvarez, MD; Anne Child MD; Bo Carlberg, MD, PhD; Ismail El- |
| 270 | Hamamsy, MD, PhD; David Chitayat, MD; Anne De Paepe, MD, PhD; Richard B. Devereaux, MD; |
| 271 | Bridgete Fernandez, MD; Josephine Grima, PhD; Maarten Groenink, MD, PhD; Gabrielle Horne, MD, |
| 272 | PhD; Yskert von Kodolitsch, MD; Ronald Lacro, MD; Scott A. LeMaire, MD; Alex V. Levin, MD; David |
| 273 | Liang, MD, PhD; Irene Maumenee, MD; Vivienne McConnell; Rocio Moran, MD; Hiroko Morisaki, MD, |
| 274 | PhD; Takayuki Morisaki, MD, PhD; Alex Pitcher, PhD; Nancy Poirier, MD; Francesco Ramirez, PhD; |
| 275 | Peter Robinson, MD; Dieter Reinhardt, PhD; Meike Rybczynski, MD; George Sandor, MD; Lynn Sakai, |
| 276 | PhD; Denver Sallee, MD; Michael N. Singh, MD; Bert Callewaert, MD, PhD; Ellen Regalado, CGC; |
| 277 | Marion A. Hofmann-Bowman, MD, PhD; Fabien Labombarda, MD; Laurence Faivre, MD, PhD; Claire |
| 278 | Bouleti, MD, PhD; Marjolijn Renard, PhD; Derek Human, BA, BM. BCh; Zoltan Szabolcs, MD, PhD; |
| 279 | Andrew Michael Crean, MD; Joseph Bavaria, MD; Apostolos Psychogios, MD; Vidyasagar Kalahasti, |
| 280 | MD; Philip Giampietro, MD, PhD; Laura Muiño- Mosquera, MD; Gisela Teixido-Tura, MD, PhD; Olivier |
| 281 | Milleron, MD; Mark Evan Lindsay, MD, PhD; Juan Manuel Bowen, MD; Shuping Ge, MD; Anthony |
| 282 | Caffarelli, MD; Jolien Roos- Hesselink, MD; Mary B. Sheppard, MD; Andrew Choong, MBBS; Enid |
| 283 | Neptune, MD; Zhou Zhou, MD, PhD; Alessandro Pini, MD; Germano Melissano, MD; Elisabetta M. |
| 284 | Mariucci, MD; Elena Cervi, MD, PhD; Melissa L. Russo, MD; Pascal-Nicoloas Bernatchez, PhD; Mitra |
| 285 | Esfandiarei, PhD; Julien Marcadier, MD; Seda Tierney, MD; Jessica Wang, MD, PhD; Kevin Michael |
| 286 | Harris, MD; Sara B. MacKay, CCGC; Andrea L. Rideout, CCGC; Sandhya Prakash, MD; Anthony Martin |
| 287 | Vandersteen, PhD; Nadine Hanna, PharmD, PhD; Carine Le Goff, PhD; Quentin Pellenc, MD; Patrick |
| 288 | Sips, PhD; Scott Michael Damrauer, MD; Lois Starr, MD, PhD; Bo Yang, MD, PhD; Jay B. Shah, MD; |

| • • • • | |
|---------|---|
| 289 | Justin T Tretter, MD; Irman Forghani, MD; Kelly Cox, MD; Siddharth K. Prakash, MD, PhD; Sachiko |
| 290 | Kanki, MD, PhD; Justin A Weigand, MD; Taylor A. Beecroft, CGC; Alan Frederick Rope, MD; Yaso |
| 291 | Emmanuel, MBChB, DPhil.; David Dichek, MD; Michelle Keir, MD; Klaus Kallenbach, MD; Talha Niaz, |
| 292 | MBBS; Mirela Tuzovic, MD; Anthony L. Estrera, MD; Timothy Carter, MD; Martin Czerny, MD; Anna |
| 293 | Sabaté Rotés, MD, PhD; Brett Carroll, MD; William T. Brinkman, MD; David R. Murdock, MD; |
| 294 | Christopher Phillips Jordan, MD. |
| 295 | |
| 296 | Sources of Funding |
| 297 | DM Milewicz and SK Prakash are funded by the Genetic Aortic Disorders Association (GADA) and |
| 298 | the John Ritter Foundation for Aortic Health. DM Milewicz is also funded by the Temerty Family |
| 299 | Foundation. |
| 300 | |
| 301 | Disclosures |
| 302 | The authors have no disclosures to report. |
| 303 | |
| 304 | Supplemental Material |

See Tables S1-S4 and Figures S1-S6. 305

306 **References**

- Hutchins, G.M., G.W. Moore, and D.K. Skoog, *The association of floppy mitral valve with disjunction of the mitral annulus fibrosus*. N Engl J Med, 1986. **314**(9): p. 535-540.
 10.1056/nejm198602273140902
- Yeerken, M., et al., Arrhythmic mitral annular disjunction syndrome: An underestimated cause of
 sudden cardiac death. Int J Cardiol, 2022. 369: p. 19-20. 10.1016/j.ijcard.2022.08.006
- Essayagh, B., et al., *Presentation and Outcome of Arrhythmic Mitral Valve Prolapse*. J Am Coll
 Cardiol, 2020. **76**(6): p. 637-649. 10.1016/j.jacc.2020.06.029
- Demolder, A., et al., Association of Mitral Annular Disjunction With Cardiovascular Outcomes
 Among Patients With Marfan Syndrome. JAMA Cardiol, 2021. 6(10): p. 1177-1186.
 10.1001/jamacardio.2021.2312
- 5. Dejgaard, L.A., et al., *The Mitral Annulus Disjunction Arrhythmic Syndrome*. J Am Coll Cardiol, 2018. **72**(14): p. 1600-1609. 10.1016/j.jacc.2018.07.070
- Berazzolo Marra, M., et al., *Morphofunctional Abnormalities of Mitral Annulus and Arrhythmic Mitral Valve Prolapse*. Circ Cardiovasc Imaging, 2016. 9(8): p. e005030.
 10.1161/circimaging.116.005030
- Carmo, P., et al., *Mitral annular disjunction in myxomatous mitral valve disease: a relevant abnormality recognizable by transthoracic echocardiography*. Cardiovasc Ultrasound, 2010. 8: p.
 53. 10.1186/1476-7120-8-53
- Bennett, S., et al., *Definition, prevalence, and clinical significance of mitral annular disjunction in different patient cohorts: A systematic review.* Echocardiography, 2022. **39**(3): p. 514-523.
 10.1111/echo.15299
- 3289.Comber, D.A., et al., Arrhythmic Mitral Valve Prolapse and Mitral Annulus Disjunction in329Heritable Aortic Disease. CJC Open, 2021. **3**(11): p. 1396-1399. 10.1016/j.cjco.2021.06.013
- Regalado, E.S., et al., Comparative Risks of Initial Aortic Events Associated With Genetic
 Thoracic Aortic Disease. J Am Coll Cardiol, 2022. 80(9): p. 857-869. 10.1016/j.jacc.2022.05.054
- Murad, A.M., et al., Spontaneous coronary artery dissection is infrequent in individuals with
 heritable thoracic aortic disease despite partially shared genetic susceptibility. Am J Med Genet
 A, 2022. 188(5): p. 1448-1456. 10.1002/ajmg.a.62661
- Caruana, M., et al., *HTAD patient pathway: Strategy for diagnostic work-up of patients and families with (suspected) heritable thoracic aortic diseases (HTAD) a statement from the HTAD working group of VASCERN.* Eur J Med Genet, 2022: p.104673. 10.1016/j.ejmg.2022.104673
- Regalado, E.S., et al., *Comparative Risks of Initial Aortic Events Associated With Genetic Thoracic Aortic Disease*. Journal of the American College of Cardiology, 2022. 80(9): p. 857-869.
 10.1016/j.jacc.2022.05.054
- Biddinger, A., et al., *Familial thoracic aortic dilatations and dissections: a case control study*. J
 Vasc Surg, 1997. 25(3): p. 506-11. 10.1016/s0741-5214(97)70261-1
- Hiratzka, L.F., et al., 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for
 the Diagnosis and Management of Patients With Thoracic Aortic Disease. Journal of the
 American College of Cardiology, 2010. 55(14): p. e27-e129. 10.1016/j.jacc.2010.02.015
- FLNA filamin A [Homo sapiens (human)]. National Library of Medicine 2022 6 November 2022.
 https://www.ncbi.nlm.nih.gov/gene/2316
- Kaw, A., et al., *Expanding ACTA2 genotypes with corresponding phenotypes overlapping with smooth muscle dysfunction syndrome*. Am J Med Genet A, 2022. 188(8): p. 2389-2396.
 10.1002/ajmg.a.62775
- Indeau, G., et al., International Registry of Patients Carrying TGFBR1 or TGFBR2 Mutations.
 Circulation: Cardiovascular Genetics, 2016. 9(6): p. 548-558.
- 353 10.1161/CIRCGENETICS.116.001485

| | | 16 |
|-----|-----|--|
| 354 | 19. | Guo, D.C., et al., LOX Mutations Predispose to Thoracic Aortic Aneurysms and Dissections. Circ |
| 355 | | Res, 2016. 118 (6): p. 928-34.10.1161/circresaha.115.307130 |
| 356 | 20. | Wallace, S.E., et al., MYLK pathogenic variants aortic disease presentation, pregnancy risk, and |
| 357 | | characterization of pathogenic missense variants. Genet Med, 2019. 21(1): p. 144-151. |
| 358 | | 10.1038/s41436-018-0038-0 |
| 359 | 21. | VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: Introducing the E- |
| 360 | | Value. Ann Intern Med. 2017;167(4):268-274. 10.7326/M16-2607 |
| 361 | 22. | Mantegazza, V., et al., Multimodality imaging assessment of mitral annular disjunction in mitral |
| 362 | | valve prolapse. Heart, 2021. 107(1): p. 25-32. 10.1136/heartjnl-2020-317330 |
| 363 | 23. | Douedi, S. and H. Douedi, <i>Mitral Regurgitation</i> , in <i>StatPearls</i> . 2023, StatPearls Publishing LLC.: |
| 364 | | Treasure Island (FL). |
| 365 | 24. | Shah, S.N., M.K. Gangwani, and T.I. Oliver, Mitral Valve Prolapse, in StatPearls. 2023, |
| 366 | | StatPearls Publishing LLC.: Treasure Island (FL). |
| 367 | 25. | Gouda, P., et al., Clinical features and complications of Loeys-Dietz syndrome: A systematic |
| 368 | | review. Int J Cardiol, 2022. 362: p. 158-167. 10.1016/j.ijcard.2022.05.065 |
| 369 | 26. | Delwarde, C., et al., Genetics and pathophysiology of mitral valve prolapse. Front Cardiovasc |
| 370 | | Med, 2023. 10: p. 1077788. 10.3389/fcvm.2023.1077788 |
| 371 | 27. | Tang, Q., et al., The Role of Transforming Growth Factor- β Signaling in Myxomatous Mitral |
| 372 | | Valve Degeneration. Front Cardiovasc Med, 2022. 9: p. 872288.10.3389/fcvm.2022.872288 |
| 373 | 28. | Crestanello, J.A., Mitral Valve Surgery for Congestive Heart Failure. Heart Fail Clin, 2018. 14(4): |
| 374 | | p. 585-600. 10.1016/j.hfc.2018.06.006 |
| 375 | 29. | Wheeler, J.B., J.S. Ikonomidis, and J.A. Jones, Connective tissue disorders and cardiovascular |
| 376 | | complications: the indomitable role of transforming growth factor-beta signaling. Adv Exp Med |
| 377 | | Biol, 2014. 802 : p. 107-27. 10.1007/978-94-007-7893-1_8 |
| 378 | 30. | Hostetler, E.M., et al., SMAD3 pathogenic variants: risk for thoracic aortic disease and |
| 379 | | associated complications from the Montalcino Aortic Consortium. J Med Genet, 2019. 56(4): p. |
| 380 | | 252-260. 10.1136/jmedgenet-2018-105583 |
| 381 | 31. | Chivulescu, M., et al., Mitral annulus disjunction is associated with adverse outcome in Marfan |
| 382 | | and Loeys-Dietz syndromes. Eur Heart J Cardiovasc Imaging, 2021. 22(9): p. 1035-1044. |
| 383 | | 10.1093/ehjci/jeaa324 |
| 384 | 32. | Eriksson, M.J., et al., Mitral annular disjunction in advanced myxomatous mitral valve disease: |
| 385 | | <i>echocardiographic detection and surgical correction</i> . J Am Soc Echocardiogr, 2005. 18 (10): p. |
| 386 | | 1014-22. 10.1016/j.echo.2005.06.013 |
| 387 | 33. | van Wijngaarden, A.L., et al., Parameters associated with ventricular arrhythmias in mitral valve |
| 388 | | prolapse with significant regurgitation. Heart, 2021. 107(5): p. 411-418 10.1136/heartjnl-2020- |
| 389 | | 317451 |
| 390 | | |
| | | |

17

392 Tables

393

394 Table 1. Characteristics of Study Cohort (n=672)

| Characteristic | Value | Missing |
|--|---------------|---------|
| Female (%) | 329 (49) | 0 |
| Height, cm (IQR) | 173 (163,183) | 64 |
| Weight, Kg (IQR) | 74 (58,93) | 57 |
| Average age at enrollment, y (IQR) | 36 (19,51) | 4 |
| Mitral valve prolapse (%) | 99 (15) | 0 |
| Mitral regurgitation (%) | 149 (22) | 0 |
| Mitral images available (%) | 240 (36) | 432 |
| Pathogenic or likely pathogenic variants (%) | 517 (77) | 0 |
| Variants of uncertain significance (%) | 155 (23) | 0 |
| TGF-βpathway variants (%) | 443 (66) | 0 |

395 cm: centimeters, kg: kilograms, y: years, IQR: interquartile range; Missing: number of MAC participants

396 with missing data.

18

| | Cohort Mitral Valve Prolapse | | | Mitral Regurgitation | | | |
|---------|------------------------------|---------|----------------|----------------------|---------|---------------|-----------|
| Gene | n (%) | n (%) | PR (CI) | E (LB) | n (%) | PR (CI) | E (LB) |
| TGFBR1 | 50 (10) | 11 (22) | 1.6 (0.9-2.9) | 2.6 (1.0) | 16 (32) | 1.5 (1.0-2.3) | 2.4 (1.0) |
| TGFBR2 | 83 (16) | 17 (20) | 1.5 (1.0-2.5) | 2.4 (1.0) | 16 (19) | 0.9 (0.6-1.4) | 1.5 (1.0) |
| TGFB2 | 77 (15) | 12 (16) | 1.2 (0.7-2.1) | 1.7 (1.0) | 13 (17) | 0.8 (0.5-1.3) | 1.8 (1.0) |
| TGFB3 | 20 (4) | 5 (25) | 1.9 (0.8-4.1) | 3.2 (1.0) | 4 (20) | 0.9 (0.4-2.3) | 1.5 (1.0) |
| SMAD3 | 80 (15) | 16 (20) | 1.5 (0.9-2.4) | 2.4 (1.0) | 29 (36) | 1.7 (1.2-2.3) | 2.8 (1.7) |
| ACTA2 | 89 (17) | 3 (3) | 0.3 (0.1-0.8) | 6.1 (1.8) | 16 (18) | 0.8 (0.5-1.3) | 1.8 (1.0) |
| COL3A1 | 62 (12) | 1 (2) | 0.1 (0.02-0.9) | 19 (1.5) | 6 (10) | 0.4 (0.2-1.0) | 4.4 (1.0) |
| FLNA | 13 (1) | 2 (15) | 1.2 (0.3-4.2) | 1.7 (1.0) | 5 (38) | 1.8 (0.9-3.6) | 3.0 (1.0) |
| MFAP5 | 2 (0) | 1 (50) | 3.7 (0.9-15) | 6.9 (1) | 1 (50) | 2.3 (0.6-9.3) | 4.0 (1.0) |
| SMAD6 | 1 (0) | 1 (100) | 7.5 (6.0-9.3) | 15 (12) | 1 (100) | 4.6 (3.9-5.4) | 8.7 (7.3) |
| MYLK | 12 (2) | 0 (0) | NA | NA | 2 (17) | 0.8 (0.2-2.8) | 1.8 (1.0) |
| MYH11 | 6 (1) | 0 (0) | NA | NA | 1 (17) | 0.8 (0.1-4.6) | 1.8 (1.0) |
| PRKG1 | 10 (3) | 0 (0) | NA | NA | 1 (10) | 0.5 (0.1-3.0) | 3.4 (1.0) |
| LOX | 6 (1) | 0 (0) | NA | NA | 1 (17) | 0.8 (0.1-4.6) | 1.8 (1.0) |
| SLC2A10 | 5 (1) | 0 (0) | NA | NA | 0 (0) | NA | NA |
| SMAD2 | 1 (0) | 0 (0) | NA | NA | 0 (0) | NA | NA |

| 398 | Table 2. Mitral | Valve Prolapse | and Mitral R | egurgitation by Gen |
|-----|-----------------|------------------|--------------|----------------------|
| 570 | | , and in the pot | | egui greation by Gen |

n: number of cases, %: percentage of cohort, Mitral valve prolapse: any degree of mitral valve prolapse,

400 Mitral regurgitation: mild, moderate, or severe mitral regurgitation, PR: prevalence ratio, E: E-value, CI:

401 confidence interval, LB: lower bound. The total prevalence of MVP was 69/517 (13%). The total

402 prevalence of MR was 112/517 (22%). The prevalence of mitral regurgitation was significantly increased 403 in MAC participants with *SMAD3* and *SMAD6* PV.

404 **Table 3. Cardiac and Aortic Events by Mitral Phenotype**

| | | v v v v v v v v v v v v v v v v v v v | | | |
|-------------------------|------------------|---------------------------------------|----------|---------------|-----------|
| Events | No MR or MVP (%) | MR and MVP (%) | n (%) | PR (CI) | E (LB) |
| Aortic surgery | 105 (29) | 14 (44) | 175 (34) | 1.5 (1.0-2.3) | 2.4 (1.0) |
| Aortic dissection | 88 (24) | 9 (28) | 145 (28) | 1.2 (0.7-2.1) | 1.7 (1.0) |
| Mitral valve surgery | 2 (0.5) | 4 (13) | 12 (2) | 23 (4.4-120) | 45 (8.3) |
| CHF | 10 (3) | 1 (3) | 22 (4) | 1.1 (0.2-8.9) | 1.4 (1.0) |
| Arrhythmia | 13 (4) | 6 (19) | 30 (6) | 5.3 (2.1-13) | 10 (3.6) |

405 MR: mild, moderate, or severe mitral regurgitation, MVP: any degree of mitral valve prolapse, CHF:

406 congestive heart failure, PR: prevalence ratio, E: E-value, CI: 95% confidence interval, LB: lower bound

407 Percentages are in parentheses. Two-tailed *P*-values were calculated using Fischer's exact test. See Table
 408 S1 for complete outcomes data. Mitral valve surgery and arrhythmia were increased in MAC participants
 409 with MB and MVD

409 with MR and MVP.

| Gene | n (%) | MAD (%) |
|----------|----------|---------|
| TGFBR1 | 22 (9) | 6 (27) |
| TGFBR2 | 45 (19) | 12 (27) |
| TGFB2 | 22 (9) | 5 (23) |
| TGFB3 | 5 (2) | 0 (0) |
| SMAD3 | 67 (28) | 29 (43) |
| SMAD6 | 1 (0) | 0 (0) |
| ACTA2 | 29 (12) | 3 (10) |
| COL3A1 | 26 (11) | 0 (0) |
| LOX | 5 (2) | 0 (0) |
| MFAP5 | 2 (1) | 1 (50) |
| MYH11 | 3 (1) | 1 (33) |
| MYLK | 1 (0) | 0 (0) |
| PRKG1 | 2 (1) | 0 (0) |
| FLNA | 8 (3) | 0 (0) |
| SCL2A10 | 2 (1) | 0 (0) |
| TGF-β PV | 162 (68) | 52 (32) |
| Other PV | 78 (32) | 5 (6) |
| Total | 240 | 57 (24) |

410 Table 4. Prevalence of MAD by Gene in MAC Participants with Available Images

411 n: number of cases, %: percentage of cohort. TGF-β: *TGFBR1*, *TGFBR2*, *TGFB2*, *TGFB3*, *SMAD3*,

412 *SMAD6*; MAD: Mitral annular disjunction.

| able 5. Characteristics of WIAC 1 articipants by WIAD 1 henotype | | | | | | |
|--|-----|-------------------------|------------|---------|--|--|
| | n | No MAD (n=183) | MAD (n=57) | Р | | |
| Age | 238 | 35 (20,49) ¹ | 33 (21,52) | 0.66 | | |
| MVP | 240 | 16 (9) | 26 (46) | < 0.001 | | |
| MR | 240 | 36 (20) | 30 (53) | < 0.001 | | |
| Arrhythmia | 235 | 20 (11) | 8 (14) | 0.64 | | |
| Aortic surgery | 239 | 63 (35) | 23 (40) | 0.53 | | |
| Aortic dissection | 240 | 37 (20) | 11 (19) | 1 | | |
| Mitral surgery | 240 | 6 (3) | 3 (5) | 0.69 | | |
| CHF | 186 | 13 (9) | 4 (8) | 1 | | |
| LVEF (%) | 153 | 62 (57,65) | 62 (57,65) | 0.80 | | |
| LA Volume (mL) | 94 | 50 (34,69) | 54 (36,75) | 0.33 | | |
| Max diameter (mm) | 164 | 38 ± 10^{2} | 39±7 | 0.55 | | |

414 **Table 5. Characteristics of MAC Participants by MAD Phenotype**

415 ¹Median (Quartile 1, quartile 3) ²Mean±SD. The individual characteristics of all MAC participants with

416 MAD are listed in Table S4. MVP: Any degree of mitral valve prolapse, MR: mild, moderate, or severe

417 mitral regurgitation, CHF: congestive heart failure, LVEF: left ventricular ejection fraction, LA: Left
 418 atrium.

22

420 Figures with Figure Legends



- 422 Figure 1. Prevalence of MAD in MAC participants with PV in TGF-β pathway genes compared to other
- 423 **HTAD genes.** MAD: Mitral annular disjunction. TGF-β pathway genes are *SKI*, *SMAD3*, *SMAD6*, *TGFBR1*,
- 424 *TGFBR2*, *TGFB2*, and *TGFB3*.
- 425

426 **Supplemental Material**



427 428 Figure S1. Prevalence of mitral valve prolapse and mitral regurgitation in MAC by variant classification.

429 All: all variants, P/LP: pathogenic and likely pathogenic variants, VUS: variants of uncertain significance, MVP: Any degree of mitral valve prolapse, MR: mild, moderate, or severe mitral regurgitation. 430

431







435 severe mitral regurgitation was included in the analysis.





438

439 Figure S3 Prevalence of mitral valve prolapse and proportion of MAC participants with PV in each HTAD

440 gene. MVP: any degree of mitral valve prolapse, %: percent cases. The prevalence of MVP was significantly

441 enriched in MAC participants with PV in *TGFBR1* and *TGFB3*. *MFAP5*, *SMAD2*, and *SMAD6* were excluded due 442 to <5 total cases.

443



Figure S4. Prevalence of mitral regurgitation and proportion of MAC participants with PV in each HTAD

gene. MR: mild, moderate, or severe mitral regurgitation. The prevalence of MR was significantly greater than
expected for *TGFBR1*. *MFAP5*, *SMAD2*, and *SMAD6* were excluded due to <5 total cases.

449

444

27

| Events | Total (%) | MVP (%) | MR (%) | MVP and MR (%) | No MVP or MR (%) |
|-------------------|-----------|----------|----------|----------------|------------------|
| Aortic Surgery | 175 (34) | 26 (38) | 57 (51)* | 14 (44) | 105 (29) |
| Aortic Dissection | 145 (28) | 18 (26) | 48 (43)* | 9 (28) | 88 (24) |
| Mitral Surgery | 12 (2) | 7 (10)* | 7 (6)* | 4 (13)* | 2 (0.5) |
| CHF | 22 (4) | 2 (3) | 10 (9)* | 1 (3) | 10 (3) |
| Arrhythmia | 30 (6) | 11 (16)* | 12 (11)* | 6 (19)* | 13 (4) |

451 **Table S1. Cardiac and aortic events stratified by mitral phenotypes**. MVP: any degree of mitral valve prolapse,

452 MR: mild, moderate, or severe mitral regurgitation, CHF: congestive heart failure. Asterisk: P < 0.05 vs. 'No MVP

453 or MR' group.

454

455

| h | 0 |
|---|---|
| L | ð |

| | | Madamata an | | | |
|----------------------|-----------|---------------|---------------|-----------|---------|
| Events | No MR (%) | Severe MR (%) | PR (CI) | E (LB) | Р |
| Aortic Surgery | 165 (33) | 10 (67) | 2.0 (1.4-3.0) | 3.4 (2.1) | 0.01 |
| Aortic Dissection | 138 (27) | 7 (47) | 1.7 (1.0-3.0) | 2.8 (1.0) | 0.14 |
| Mitral Surgery | 8 (2) | 4 (27) | 17 (5.7-50) | 34 (11) | < 0.001 |
| CHF | 7 (1) | 5 (33) | 24 (8.6-70) | 48 (17) | < 0.001 |
| Arrhythmia | 26 (5) | 4 (27) | 5.1 (2.1-13) | 9.7 (3.6) | 0.008 |

456 **Table S2. Cardiac and aortic events of MAC participants with moderate or severe MR.** MR: moderate or

severe mitral regurgitation, CHF: congestive heart failure, PR: prevalence ratio, E: E-value, CI: 95% confidence
interval, LB: Lower bound. Percentages are in parentheses. Two-tailed *P*-values were calculated using Fisher's
exact test.

29

| Endpoint | Probands (n=243, %) | Relatives (n=185, %) | PR (CI) | E (LB) | Р |
|--|---------------------|----------------------|---------------|-----------|---------|
| MR | 59 (24) | 23 (12) | 2.0 (1.3-3.0) | 3.4 (1.9) | 0.003 |
| MVP | 36 (15) | 21 (11) | 1.3 (0.8-2.2) | 1.9 (1.0) | 0.32 |
| MAD* | 22 (23) | 7 (14) | 1.7 (0.8-3.6) | 2.8 (1.0) | 0.27 |
| Pathological Mitral Phenotypes Without Aortic Dilation* | 5 (5) | 10 (20) | 0.3 (0.1-0.7) | 20 (6.1) | 0.009 |
| Aortic Surgery | 103 (42) | 38 (21) | 2.1 (1.5-2.8) | 3.6 (2.4) | < 0.001 |
| Aortic Dissection | 90 (37) | 35 (19) | 2.0 (1.4-2.8) | 3.4 (2.1) | < 0.001 |
| Mitral Surgery | 7 (3) | 2 (1) | 2.7 (0.6-13) | 4.8 (1.0) | 0.31 |
| CHF | 6 (2) | 4 (2) | 1.1 (0.3-4.0) | 1.4 (1.0) | 1 |
| Arrhythmia | 9 (4) | 10 (5) | 0.7 (0.3-1.7) | 2.2 (1.0) | 0.48 |

462 **Table S3. Characteristics of MAC participants by proband status.** MR: mild, moderate, or severe mitral

463 regurgitation, MVP: any degree of mitral valve prolapse, MAD: mitral annular disjunction, CHF: congestive heart

464 failure, PR: prevalence ratio, E: E-value, CI: 95% confidence interval, LB: Lower bound. *Analysis was confined

465 to MAC probands (n = 95) and relatives (n = 50) with available images. Aortic dilation: Z-score > 3, Pathological

466 mitral phenotypes: \geq mild MR, \geq 10 mm MAD, or MAD with MVP. MR, aortic surgery, and aortic dissection were

467 more prevalent in probands, while predominant mitral phenotypes were more prevalent in relatives.

| Gene | n (%) | Aortic Dilation (%) | Pathological Mitral Phenotypes (%) | Pathological Mitral Phenotypes without Aortic Dilation (%) |
|---------|---------|---------------------|---------------------------------------|--|
| TGFBR1 | 22 (9) | 11 (50) | 6 (27) | 2 (9) |
| TGFBR2 | 45 (19) | 18 (40) | 10 (22) | 1 (2) |
| TGFB2 | 22 (9) | 3 (14) | 4 (18) | 0 (0) |
| TGFB3 | 5 (2) | 2 (4) | 0 (0) | 0 (0) |
| SMAD3 | 67 (28) | 10 (15) | 17 (25) | 12 (18) |
| SMAD6 | 1 (0) | 1 (100) | 0 (0) | 0 (0) |
| ACTA2 | 29 (12) | 10 (35) | 2 (7) | 0 (0) |
| COL3A1 | 26 (11) | 3 (12) | 0 (0) | 0 (0) |
| LOX | 5 (2) | 3 (60) | 0 (0) | 0 (0) |
| MFAP5 | 2 (1) | 0 (0) | 0 (0) | 0 (0) |
| MYH11 | 3 (1) | 2 (67) | 0 (0) | 0 (0) |
| MYLK | 1 (0) | 0 (0) | 0 (0) | 0 (0) |
| PRKG1 | 2 (1) | 1 (50) | 0 (0) | 0 (0) |
| FLNA | 8 (3) | 0 (0) | 0 (0) | 0 (0) |
| SCL2A10 | 2 (1) | 0 (0) | 0 (0) | 0 (0) |

469 Table S4. Proportion of MAC participants with pathological mitral phenotypes and/or aortic dilation by

470 HTAD gene. Aortic dilation: Z-score > 3, Pathological mitral phenotypes: >mild MR, ≥ 10 mm MAD, or MAD with MVP. Analysis was limited to the subset of MAC participants with available images (n = 240).

471

31



473

474 Figure S5. Prevalence of MAD and proportion of MAC participants with PV in each HTAD gene. MAD:

475 mitral annular disjunction. The prevalence of MAD was significantly enriched in MAC participants with PV in
 476 *TGFBR1*, *TGFB2*, and *SMAD3*. *MFAP5*, *MYH11*, *MYLK*, *PRKG1*, *SMAD6*, and *SLC2A10* were excluded due to <

477 5 cases. Limited to the subset of MAC participants with available images (n=240).

32

| | Z | Odds Ratio | 95% CI | Р |
|-------------------|-----|-------------------|-----------|-------|
| Age | 2.5 | 1.06 | 1.01-1.11 | 0.013 |
| Male sex | 0.6 | 1.53 | 0.38-6.25 | 0.55 |
| Missense mutation | 2.6 | 10.8 | 1.78-65 | 0.01 |
| MAD | 1.8 | 0.19 | 0.03-1.18 | 0.074 |
| MVP or MR | 2.8 | 15.9 | 2.35-107 | 0.004 |

479 480

478









Figure S6. Logistic regression of composite clinical events (aortic surgery, mitral surgery, aortic dissection, 483 arrhythmia, CHF) for MAC participants with SMAD3 PV. MVP: any degree of mitral valve prolapse, MR: mild,

484 moderate, or severe mitral regurgitation.